New Customers Get 10% Off – Use Code: LUX10

Amylin Analog (Peptide)

GLP-3 (RT) Cagrilintide

5.0 Reviews

GLP-3GLP-3 RTPeptides

A selective estrogen receptor modulator (SERM) presented in 25 mg capsules, studied for its effects on endogenous testosterone regulation and hormonal balance in research settings. Premium Research Compound.

Original price was: $99.99.Current price is: $89.99.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How GLP-3 (RT) Cagrilintide Works

The Science, Simplified

Long-Acting Amylin Agonism

Cagrilintide is a long-acting, acylated analog of the hormone amylin. It acts as a non-selective agonist for both the amylin receptors (AMYR) and the calcitonin G protein-coupled receptor (CTR).
Key insight: While GLP-1 peptides primarily target the gut and pancreas, amylin analogs work directly on the hindbrain (Area Postrema) to signal satiety. In research models, this creates a distinct pathway for appetite suppression that, when combined with GLP-1/GIP agonists, can produce weight loss results far exceeding monotherapy.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Preservation of Lean Mass

One of the most significant findings in recent Cagrilintide studies is its ability to facilitate "quality" weight loss.

Key insight: Preclinical studies indicate that subchronic application reduces food intake and body weight primarily by reducing relative fat mass while maintaining relative lean mass. This “muscle-sparing” effect is a major differentiator for researchers looking to improve metabolic composition rather than just lowering a number on a scale.

Synergistic Weight Reduction

Cagrilintide is often researched alongside Semaglutide (in a combination known as "CagriSema").

Key insight: In a 32-week Phase 2 trial, the combination of Cagrilintide and Semaglutide resulted in significantly greater weight loss than Semaglutide alone. It works by slowing gastric emptying and modulating glucose spikes, creating a multi-faceted approach to managing energy homeostasis.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

Cagrilintide is currently in Phase 3 clinical trials for obesity and Type 2 diabetes. It is generally well-tolerated, though its potent effect on the digestive system is the primary focus of safety monitoring.

🧿 Common Digestive Issues

45%

Nausea

mild

5%

Vomiting

mild

10%

Admin-Site Reactions

mild

Safety Advantage

Non-Suppressive Elevation

  • Central Satiety: Unlike traditional diet drugs that rely on the central nervous system (CNS) stimulants, Cagrilintide works on the brain's natural satiety receptors, avoiding the "jittery" feeling associated with sympathomimetic agents.
  • Stable Half-Life: It has a pharmacokinetic profile with a half-life of approximately 170–180 hours (7–8 days), which supports a stable once-weekly research protocol.
  • Low Hypoglycemia Risk: As an amylin analog, it helps regulate blood sugar without significantly increasing the risk of low blood sugar (hypoglycemia) when researched as a standalone agent.

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for this amylin analog

🔬 Molecular Profile

What IsGLP-3 (RT) Cagrilintide?

Full Name

Cagrilintide

CAS Number

1415456-99-3

Molecular Weight

~4,409 Da

Sequence

37-Amino Acid Analog

Purity

≥99%

🧊 Storage Requirements

Stability Information

Lyophilized (powder)

Store at -20°C

for up to 12 months.

Reconstituted

Store at 2-8°C

use within 21 days.

Sensitivity

Moisture and light sensitive;

store under nitrogen if possible.

📋Research Status

Development History

Clinical Stage

Phase III (Novo Nordisk)

Classification

Amylin / CTR Agonist

Primary Goal

Obesity & Metabolic Health

US Status

Investigational Research Compound

Frequently Asked Questions

Common questions about GLP-3 (RT) Cagrilintide

Semaglutide is a GLP-1 receptor agonist. Cagrilintide is an amylin analog. They target different receptors in the brain. Think of Semaglutide as reducing the "urge" to eat and Cagrilintide as increasing the "feeling" of being full.
Yes, it is a potent monotherapy. However, the most exciting research involves its use as a "booster" for other metabolic agents. When used with Retatrutide or Semaglutide, it often helps overcome weight-loss plateaus in research subjects.
CagriSema is a co-formulation of Cagrilintide and Semaglutide. In clinical trials, this combination produced more absolute weight loss than any other currently approved anti-obesity medication.
Current research is very promising regarding body composition. Unlike standard caloric restriction which can lead to significant muscle loss, Cagrilintide research has shown a preservation of lean mass, making it a "quality" weight loss agent.
No. It is currently in Phase 3 global clinical trials. It is sold strictly for laboratory research purposes and is not intended for human consumption or medical use.

Sources & References

Peer-reviewed research

  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square